With Opnet's Marc Cohen on Board, Biotech Startup ONCoPEP Raises $3.7M

With Opnet's Marc Cohen on Board, Biotech Startup ONCoPEP Raises $3.7M

BETHESDA, Md. -- Biotechnology startup ONCoPEP, Inc. has raised $3.65 million from a $4.5 million offering of series A stock while attracting 12 investors.

CEO Doris Peterkin is named in the filing along with the following directors:

- Marc Cohen from Bethesda, Md.-based Opnet
- Nikhil Munshi from the Dana-Farber Cancer Institute in Boston
- Kenneth Anderson also from the Dana-Farber Cancer Institute in Boston
- Joslyn Dobson
- Bruce Downey
- Elena Prokupets

Peterkin was previously the CEO of Healagenics and a consultant with Arthro Kinetics. She attended Virginia Polytechnic Institute and State University as well as Boston University School of Management.

OncoPep, based in North Andover, Mass., is developing a vaccine designed to prevent multiple myeloma by treating patients who have a precursor of the disease.

Multiple myeloma, whose current treatments can only extend the lives of patients without curing the disease, is a cancer of blood plasma cells that develops when abnormal plasma cells in bone marrow multiply and accumulate and eventually damage bones and other tissues in the body.

SEC filing: http://tinyurl.com/3bxza6a

Bio from BusinessWeek:

Marc Cohen:
Mr. Marc A. Cohen is a Co-Founder of OPNET Technologies Inc. and has been its Chief Executive Officer since 1994. Mr. Cohen serves as Secretary and Treasurer of OPNET Technologies Inc. He is a Co-Founder of Acetylon Pharmaceuticals, Inc. and also serves as its Chairman. From 1986 to 1992, Mr. Cohen served as a Consultant of Booz Allen Hamilton Inc. or Booz Allen, an international management and consulting company. Mr. Cohen has been Chairman at OPNET Technologies Inc. since its inception in 1986. He also serves as a Trustee of the Dana Farber Cancer Institute in Boston, Massachusetts. Mr. Cohen received a Bachelor's degree in Engineering Science from Harvard University and a Master's degree in Electrical Engineering from Stanford University.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.